$HURA

2021 Q2 Form 10-Q Financial Statement

#000156459021027558 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.666M $2.760M $1.470M
YoY Change 81.36% 155.56% -24.23%
% of Gross Profit
Research & Development $4.031M $3.843M $1.300M
YoY Change 210.08% 327.47% 35.42%
% of Gross Profit
Depreciation & Amortization $12.00K $20.00K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $6.697M $6.605M $2.770M
YoY Change 141.77% 234.26% -4.48%
Operating Profit
YoY Change
Interest Expense -$35.00K $7.000K $0.00
YoY Change -65.0% -100.0%
% of Operating Profit
Other Income/Expense, Net -$30.00K
YoY Change -257.89%
Pretax Income -$6.732M -$6.640M -$3.820M
YoY Change 76.23% 238.78% 48.06%
Income Tax
% Of Pretax Income
Net Earnings -$6.732M -$6.635M -$3.820M
YoY Change 76.23% 239.04% 48.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23
Diluted Earnings Per Share -$207.5K -$226.9K -$334.2K
COMMON SHARES
Basic Shares Outstanding 32.62M 29.27M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.54M $15.72M $2.390M
YoY Change 340.88% 216.3% -35.75%
Cash & Equivalents $10.54M $15.72M $2.392M
Short-Term Investments
Other Short-Term Assets $1.256M $860.0K $450.0K
YoY Change 179.11% 681.82% 60.71%
Inventory
Prepaid Expenses $756.0K $363.0K $365.0K
Receivables
Other Receivables
Total Short-Term Assets $11.79M $16.59M $2.851M
YoY Change 313.64% 225.25% -29.17%
LONG-TERM ASSETS
Property, Plant & Equipment $150.0K $165.0K $2.000K
YoY Change 7400.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.600M $2.100M $80.00K
YoY Change 1900.0%
Total Long-Term Assets $1.750M $2.265M $87.00K
YoY Change 1911.49% 621.27%
TOTAL ASSETS
Total Short-Term Assets $11.79M $16.59M $2.851M
Total Long-Term Assets $1.750M $2.265M $87.00K
Total Assets $13.54M $18.85M $2.938M
YoY Change 360.96% 269.67% -27.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.219M $1.650M $2.010M
YoY Change 10.4% 51.38% 15.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $500.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.780M $2.533M $2.675M
YoY Change 3.93% 83.55% 29.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $182.0K $200.0K
YoY Change
Total Long-Term Liabilities $182.0K $200.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.780M $2.533M $2.675M
Total Long-Term Liabilities $182.0K $200.0K $0.00
Total Liabilities $2.962M $2.735M $2.675M
YoY Change 10.73% 98.19% 29.24%
SHAREHOLDERS EQUITY
Retained Earnings -$111.2M -$104.5M -$69.72M
YoY Change 59.53% 15.09%
Common Stock $106.9M $100.9M $65.16M
YoY Change 63.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.58M $16.12M $263.0K
YoY Change
Total Liabilities & Shareholders Equity $13.54M $18.85M $2.938M
YoY Change 360.96% 269.67% -27.23%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q2
OPERATING ACTIVITIES
Net Income -$6.732M -$6.635M -$3.820M
YoY Change 76.23% 239.04% 48.06%
Depreciation, Depletion And Amortization $12.00K $20.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$4.690M -$4.630M -$2.580M
YoY Change 81.78% 237.96% 41.76%
INVESTING ACTIVITIES
Capital Expenditures $2.000K -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.000K $0.00
YoY Change
Cash From Investing Activities $4.000K -$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -489.0K 3.190M 0.000
YoY Change -32000.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.690M -4.630M -2.580M
Cash From Investing Activities 4.000K -10.00K
Cash From Financing Activities -489.0K 3.190M 0.000
Net Change In Cash -5.175M -1.450M -2.580M
YoY Change 100.58% 5.07% -265.38%
FREE CASH FLOW
Cash From Operating Activities -$4.690M -$4.630M -$2.580M
Capital Expenditures $2.000K -$10.00K
Free Cash Flow -$4.692M -$4.620M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-97000
CY2020Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
17000
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32617939
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000
dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1077000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
6605000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
1976000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2021Q1 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
23000
CY2021Q1 us-gaap Interest Expense
InterestExpense
7000
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1000
CY2021Q1 ktra Clinical Trial Deposit Current
ClinicalTrialDepositCurrent
500000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2392000
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15718000
dei Trading Symbol
TradingSymbol
KTRA
dei Security12b Title
Security12bTitle
Common Stock
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
363000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Transition Report
DocumentTransitionReport
false
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
356000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
664000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
32000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
100828000
CY2021Q1 us-gaap Liabilities
Liabilities
2735000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
2851000
CY2021Q1 ktra Clinical Trial Deposit Non Current
ClinicalTrialDepositNonCurrent
2100000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2020Q2 us-gaap Deferred Costs
DeferredCosts
85000
CY2021Q1 us-gaap Assets
Assets
18853000
CY2020Q2 us-gaap Assets
Assets
2938000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1645000
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2011000
CY2021Q1 us-gaap Loans Payable Current
LoansPayableCurrent
503000
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
385000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2533000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2675000
CY2021Q1 ktra Milestone Payment Liability
MilestonePaymentLiability
202000
CY2021Q1 ktra Taxes And Other Receivables Current
TaxesAndOtherReceivablesCurrent
7000
CY2020Q2 ktra Taxes And Other Receivables Current
TaxesAndOtherReceivablesCurrent
9000
CY2020Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
94000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
16588000
CY2020Q2 us-gaap Liabilities
Liabilities
2675000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104489000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
16118000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18853000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2332000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7091000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3045000
ktra Merger Costs
MergerCosts
500000
ktra In Progress Research And Development Expense
InProgressResearchAndDevelopmentExpense
16094000
us-gaap Operating Expenses
OperatingExpenses
31469000
us-gaap Operating Expenses
OperatingExpenses
5377000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
74000
us-gaap Interest Expense
InterestExpense
23000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
74000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
74000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1957000
us-gaap Net Income Loss
NetIncomeLoss
-31566000
us-gaap Net Income Loss
NetIncomeLoss
-5303000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69721000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7784000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2938000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
899000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
65148000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2762000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
263000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11458000
CY2020Q3 ktra Adgero Merger Value
AdgeroMergerValue
16725000
CY2020Q3 ktra Issuance Of Series C Preferred Stock
IssuanceOfSeriesCPreferredStock
25028000
CY2020Q3 ktra Series C Preferred Stock Issue Costs
SeriesCPreferredStockIssueCosts
-3386000
CY2020Q3 ktra Exercise Of Warrants For Cash
ExerciseOfWarrantsForCash
994000
CY2020Q3 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
45000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
405000
CY2020Q3 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-19518000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1957000
us-gaap Net Income Loss
NetIncomeLoss
-31566000
us-gaap Net Income Loss
NetIncomeLoss
-5303000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
3181000
CY2021Q1 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
2000
CY2020Q1 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
2000
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
6000
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
6000
CY2021Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6000
CY2020Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
15000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6643000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1960000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34768000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5315000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29273000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11417000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23701000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10117000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
263000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
20554000
CY2020Q4 ktra Series C Preferred Stock Issue Costs
SeriesCPreferredStockIssueCosts
-69000
CY2020Q4 ktra Exercise Of Warrants For Cash
ExerciseOfWarrantsForCash
186000
CY2020Q4 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
183000
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2125000
CY2020Q4 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2020Q4 us-gaap Profit Loss
ProfitLoss
-5413000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17585000
CY2021Q1 ktra Exercise Of Warrants For Cash
ExerciseOfWarrantsForCash
3219000
CY2021Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
210000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1719000
CY2021Q1 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-6635000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
16118000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1968000
CY2019Q3 ktra Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
6583000
CY2019Q3 ktra Exercise Of Pre Funded Warrants For Cash
ExerciseOfPreFundedWarrantsForCash
26000
CY2019Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5000
CY2019Q3 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-1606000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
7025000
CY2019Q4 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
35000
CY2019Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5350000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
969000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
8000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
964000
ktra Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
21598000
ktra Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
6583000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4399000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
27000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
42000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-1957000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3721000
ktra Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
133000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4248000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
307000
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160000
CY2019Q4 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
CY2019Q4 us-gaap Profit Loss
ProfitLoss
-1740000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5481000
CY2020Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
99000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
96000
CY2020Q1 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-2000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2596000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-165000
ktra Increase Decrease In Taxes And Other Receivables
IncreaseDecreaseInTaxesAndOtherReceivables
-2000
ktra Increase Decrease In Taxes And Other Receivables
IncreaseDecreaseInTaxesAndOtherReceivables
-16000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-640000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-659000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-279000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-29000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14171000
us-gaap Profit Loss
ProfitLoss
-31566000
us-gaap Profit Loss
ProfitLoss
-5303000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000
us-gaap Depreciation
Depreciation
15000
ktra In Progress Research And Development Expense
InProgressResearchAndDevelopmentExpense
16094000
ktra Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
-14000
us-gaap Interest Expense
InterestExpense
23000
ktra Amortization Of Deferred Loan Costs
AmortizationOfDeferredLoanCosts
74000
ktra Issuance Of Stock For Services
IssuanceOfStockForServices
12000
ktra Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
438000
us-gaap Proceeds From Construction Loans Payable
ProceedsFromConstructionLoansPayable
500000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
6000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
6000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26533000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6604000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13326000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1254000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2392000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3719000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15718000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4973000
us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of operations, corporate history, and going concern and management plans</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of operations</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) (the “Company”) is a clinical stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources.  The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among Adgero Acquisition Corp., the Company’s wholly-owned subsidiary incorporated in the State of Delaware (“Merger Sub”), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”). On August 19, 2020, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into Adgero (the “Merger”), the separate corporate existence of Merger Sub ceased and Adgero continued its existence under Delaware law as the surviving corporation in the Merger and became a direct, wholly-owned subsidiary of the Company. As a result of the Merger, each issued and outstanding share of Adgero common stock, par value $0.0001 per share (the “Adgero Common Stock”) (other than treasury shares held by Adgero), was converted automatically into 1.5740 shares (the “Exchange Ratio”) of the Company’s common stock per share of Adgero Common Stock, and cash in lieu of any fractional shares. Also, each outstanding warrant to purchase Adgero Common Stock was converted into a warrant exercisable for that number of shares of the Company’s common stock equal to the product of (x) the aggregate number of shares of Adgero Common Stock for which such warrant was exercisable and (y) the Exchange Ratio.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the completion of the Merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on Nasdaq under the symbol “KTRA”.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate history</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Going concern and management plans</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business</span><span style="Background-color:#FFFFFF;color:#000000;">.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">For the nine months ended March 31, 2021, the Company reported a loss of $31,566 and a negative cash flow from operations of $14,171. The Company had an accumulated deficit of $104,489 and had cash and cash equivalents of $15,718 as of March 31, 2021. The Company is in the clinical stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. In the near future, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these condensed consolidated interim financial statements.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to secure the necessary financing through the issue of new equity and/or the entering into of strategic partnership arrangements but the </span>ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic. <span style="Background-color:#FFFFFF;">The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.  Such adjustments could be material.</span></p>
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1.5740 shares
us-gaap Net Income Loss
NetIncomeLoss
-31566000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14171000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104489000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15718000
ktra Substantial Doubt About Companys Ability To Continues Going Concern Period
SubstantialDoubtAboutCompanysAbilityToContinuesGoingConcernPeriod
P1Y
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</p>
CY2021Q1 ktra Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
1708000
ktra Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
2958000
ktra Deposits Payments
DepositsPayments
2600000
ktra Deposits Payments Anticipated Short Term
DepositsPaymentsAnticipatedShortTerm
500000
ktra Deposits Payments Anticipated Long Term
DepositsPaymentsAnticipatedLongTerm
2100000
ktra In Progress Research And Development Expense
InProgressResearchAndDevelopmentExpense
16094000
us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
three years
us-gaap Legal Fees
LegalFees
1553000
CY2020 us-gaap Legal Fees
LegalFees
1054000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
300000
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
240000
us-gaap Payments To Employees
PaymentsToEmployees
60000
ktra Number Of Milestone
NumberOfMilestone
2
ktra Milestone Payment Liability Addition
MilestonePaymentLiabilityAddition
188000
ktra Milestone Payment Liability Change In Fair Value Estimate
MilestonePaymentLiabilityChangeInFairValueEstimate
14000
CY2021Q1 ktra Milestone Payment Liability
MilestonePaymentLiability
202000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
180000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
385000
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
664000
ktra Underwritten Public Offerings Description
UnderwrittenPublicOfferingsDescription
the Company closed on the sale of (i) 4,895 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,763 shares of Common Stock (“2020 Investor Warrants”), including 800 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,013 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant.
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
280000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
53000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.61
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6453000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2128000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1718000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
96000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4248000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
307000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
858000
CY2020Q2 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
0.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4999000
ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
1.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1518000
ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
1.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
14000
ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice
1.42
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4325000
CY2021Q1 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
1.62
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
15000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
3181000
ktra Non Cash Issue Costs
NonCashIssueCosts
3287000
CY2021Q1 us-gaap Loans Payable Fair Value Disclosure
LoansPayableFairValueDisclosure
523000

Files In Submission

Name View Source Status
0001564590-21-027558-index-headers.html Edgar Link pending
0001564590-21-027558-index.html Edgar Link pending
0001564590-21-027558.txt Edgar Link pending
0001564590-21-027558-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwl3ibqfw2zi000001.jpg Edgar Link pending
gwl3ibqfw2zi000002.jpg Edgar Link pending
gwl3ibqfw2zi000003.jpg Edgar Link pending
ktra-10q_20210331.htm Edgar Link pending
ktra-10q_20210331_htm.xml Edgar Link completed
ktra-20210331.xsd Edgar Link pending
ktra-20210331_cal.xml Edgar Link unprocessable
ktra-20210331_def.xml Edgar Link unprocessable
ktra-20210331_lab.xml Edgar Link unprocessable
ktra-20210331_pre.xml Edgar Link unprocessable
ktra-ex311_6.htm Edgar Link pending
ktra-ex312_7.htm Edgar Link pending
ktra-ex321_9.htm Edgar Link pending
ktra-ex322_8.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending